Effectiveness of Different THR Products in Adult Population

What Was Tested

This registered phase 3 trial tested Therapeutic nicotine (patch, non-peptide).

It had two arms (groups): one (active comparator) and one (active comparator).

The registry classes the interventions as device and drug.

More on the Plan

This is a two-arm, parallel randomized controlled trial with a 12 weeks treatment duration and long-term 52 weeks follow-up.

Outpatient, and walk-in clinics, and advertising will be used to recruit participants from the general population.

Individual counselling regarding smoking cessation will be provided to the participants using EC as well as nicotine patches.

Exhaled carbon monoxide assessment will be used at the trial site to quantify biochemically validated smoking abstinence (exhaled carbon monoxide levels above ten ppm regarded as indicator of current smoking).

Who Took Part

The registry lists 258 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: Both genders of legal age allowed for smoking as per country law. Exhaled breath CO (eCO) level \> 10 ppm. Wish to quit smoking. Able to conform with all study procedures. Have a mobile phone.

The full record lists 7 inclusion and 4 exclusion criteria; among the exclusions: pregnant and breastfeeding women; using other smoking cessation medications (including other forms of nrt other than patch, bupropion, clonidine, nortriptyline or varenicline); having any contraindications to products such as cardiovascular history.

How the Study Was Run

Design: randomized, parallel-group and open-label.

The participants were allocated by chance, so the Therapeutic nicotine (patch, non-peptide) group and the comparison group should start out alike.

The Therapeutic nicotine (patch, non-peptide) group and the comparison group ran side by side rather than switching.

Being open-label, the Therapeutic nicotine (patch, non-peptide) study did not mask who received what.

It started in 2024-06 with completion listed for 2025-03.

It ran at 1 site in Pakistan.

Its stated primary purpose is treatment.

What Was Measured

The main thing measured (primary outcome): Point-prevalence abstinence (time frame: 12 weeks).

It also tracked 5 secondary outcomes, for example Seven-day point prevalence, Use of tobacco combustible cigarettes, Perception of the product and Adverse events.

What This Means in Plain Language

Put simply, this is a phase 3, randomized trial of Therapeutic nicotine (patch, non-peptide) in 258 people.

Its status is unknown; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.